Bio-Rad Laboratories (BIO-B) Cash & Current Investments (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Cash & Current Investments data on file, last reported at $1.6 billion in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $1.6 billion, down 5.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 5.76% YoY), and the FY2025 annual result was $1.5 billion, down 7.44% from the prior year.
• Cash & Current Investments advanced to $1.6 billion in Q1 2026 per BIO-B's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $2.1 billion in Q1 2022 and troughed at $409.4 million in Q4 2023.
• A 5-year average of $1.1 billion and a median of $1.4 billion in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 77.35% in 2023, then soared 306.57% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $439.8 million in 2022, then dropped by 6.91% to $409.4 million in 2023, then soared by 306.57% to $1.7 billion in 2024, then fell by 7.44% to $1.5 billion in 2025, then grew by 1.56% to $1.6 billion in 2026.
• Business Quant data shows BIO-B's Cash & Current Investments at $1.6 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.